An Organellar Nα-Acetyltransferase, Naa60, Acetylates Cytosolic N Termini of Transmembrane Proteins and Maintains Golgi Integrity

Highlights

- Naa60 is an organelle N-terminal acetyltransferase, and it acts on the cytosolic face
- Most transmembrane proteins are Nt-acetylated, and Naa60 acts specifically on these
- Naa60 mainly localizes to the Golgi and is essential for Golgi ribbon structure
- PROMPT, a novel assay for membrane topology of proteins, is presented

In Brief
Aksnes et al. show that N-terminal acetylation, a common modification of soluble eukaryotic proteins, is also frequent among transmembrane proteins. They find Naa60 to be an organelle-associated N-terminal acetyltransferase, with cytosolic activity toward N termini of transmembrane proteins, likely involved in the maintenance of the Golgi’s structural integrity.

Authors
Henriette Aksnes, Petra Van Damme, ..., Kris Gevaert, Thomas Arnesen

Correspondence
thomas.arnesen@mbi.uib.no

Cell Reports
INTRODUCTION

N-terminal acetylation is a major and vital protein modification catalyzed by N-terminal acetyltransferases (NATs). NatF, or Nα-acetyltransferase 60 (Naa60), was recently identified as a NAT in multicellular eukaryotes. Here, we find that Naa60 differs significantly from other NATs, suggesting its unique role in the maintenance of the Golgi's structural integrity.

SUMMARY

NAA60 is a new membrane topology assay named PROMPT (Proteins and Maintains Golgi Integrity) that can be used to establish N-terminal acetylome. This is the first report of an organellar Nα-acetyltransferase in E. coli, Acetobacter xylinum, and Drosophila melanogaster. Naa60 faces the cytosolic side of intracellular membranes. An Nt-acetylome analysis revealed that Naa60 is involved in the acetylation of cytosolic N termini of transmembrane proteins and maintains Golgi integrity.

Correspondence:
Mathias Ziegler, Thomas Vikestad Kalvik, Kris Gevaert, Nina Glomnes, Sonja Ljostveit, and Thomas Arnesen

An Organellar Nα-Acetyltransferase, Naa60, Acetylates Cytosolic N Termini of Transmembrane Proteins and Maintains Golgi Integrity

Henriette Aksnes, Petra Van Damme, Marianne Goris, Kristian K. Starheim, Michaël Marie, Svein Isungset Støve, Camilla Hoel, Thomas Vikestad Kalvik, Kristine Hole, Nina Glomnes, Clemens Furnes, Sonja Ljostveit, Mathias Ziegler, Marc Niere, Kris Gevaert, and Thomas Arnesen

1Department of Molecular Biology, University of Bergen, 5020 Bergen, Norway
2Department of Medical Protein Research, VIB, 9000 Ghent, Belgium
3Department of Biochemistry, Ghent University, 9000 Ghent, Belgium
4Department of Clinical Science, University of Bergen, 5020 Bergen, Norway
5Department of Surgery, Haukeland University Hospital, 5021 Bergen, Norway

*Correspondence: thomas.arnesen@mbl.uib.no
http://dx.doi.org/10.1016/j.celrep.2015.01.053

This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/3.0/).
SUMMARY

N-terminal acetylation is a major and vital protein modification catalyzed by N-terminal acetyltransferases (NATs). NatF, or Nα-acetyltransferase 60 (Naa60), was recently identified as a NAT in multicellular eukaryotes. Here, we find that Naa60 differs from all other known NATs by its Golgi localization. A new membrane topology assay named PROMPT and a selective membrane permeabilization assay established that Naa60 faces the cytosolic side of intracellular membranes. An Nt-acetylome analysis of NAA60-knockdown cells revealed that Naa60, as opposed to other NATs, specifically acetylates transmembrane proteins and has a preference for N termini facing the cytosol. Moreover, NAA60 knockdown causes Golgi fragmentation, indicating an important role in the maintenance of the Golgi’s structural integrity. This work identifies a NAT associated with membranous compartments and establishes N-terminal acetylation as a common modification among transmembrane proteins, a thus-far poorly characterized part of the N-terminal acetylome.

ACKNOWLEDGMENTS

This work was supported by grants from the Norwegian Cancer Society (to T.A.), The Bergen Research Foundation BFS (to T.A.), the Research Council of Norway (grants 197136 and 230865 to T.A.), and the Western Norway Regional Health Authority (to T.A.). P.V.D. acknowledges support from the Research Foundation - Flanders (FWO-Vlaanderen; project number G.0269.13N). Previous students in the Arnesen lab, Janniche Torsvik and Einar Birkeland, are thanked for earlier work on Naa60. Professors Rein Aasland and Anne-Marie Szilvay are acknowledged for the idea of specific protein cleavage as a tool for localization studies.

Received: July 7, 2014
Revised: December 23, 2014
Accepted: January 20, 2015
Published: February 26, 2015
**EXPERIMENTAL PROCEDURES**

HeLa, HeLaS3, A-431, and 293 cells were transfected with Fugene 6 (Roche/ Promega), X-tremeGENE 9 (Roche), or Effectene (PROMPT validation experiments) according to the manufacturer’s protocol. 0.25–0.5 μg DNA was used per ml culture medium. Unless otherwise indicated, cells were used for downstream experiments 12–24 hr posttransfection. NAA60 knockdown was performed by transfection using Dharmafect 1 (GE Dharmacon) or HiPerFect (QIAGEN) according to the respective manufacturer’s protocols, with the addition of 5 nM pan-caspase inhibitor Z-VAD-FMK (renewed every 24 hr by replacing half of the culture medium). Cells were harvested or fixed approximately 72 or 96 hr post-siRNA transfection. For preparation of crude A-431 cell fractions, cells were harvested and dissolved in homogenization buffer (0.25 M sucrose, 1 mM EDTA, 20 mM HEPES-NaOH [pH 7.4]), after which nuclei were removed by sedimentation at 3,000 × g for 5 min and organelles and cytosol were separated by centrifugation at 17,000 × g for 20 min. SILAC-labeled fractionated A-431 cells were used for N-terminal COFRADIC analysis, as previously described (Staes et al., 2011; Van Damme et al., 2009) and detailed in the Supplemental Experimental Procedures.

Standard procedures were followed for immunocytochemistry, and the buffers, antibodies, and incubation times are given in detail in the Supplemental Experimental Procedures. Fluorescent images in Figures 3B, 6A, and 6D were obtained on a Leica TCS SP2 AOBS. Fluorescent images in Figures 6A and 6D were obtained on z stacks of 0.2- to 0.3-μm-thick optical sections spanning the entire depth of Golgi complexes and are shown as maximum-intensity projections, and insets are presented as projections of two or three successive sections. All other fluorescent images were obtained on a Leica DMI6000 B wide field microscope. Further instrument details can be found in the Supplemental Experimental Procedures. The acquired images were processed using the Photoshop CS5 image software (Adobe Systems).

Detailed information on additional procedures, including bioinformatics tools used and construction of plasmids, are available in the Supplemental Experimental Procedures.

**SUPPLEMENTAL INFORMATION**

Supplemental Information includes Supplemental Experimental Procedures, five figures, and two tables and can be found with this article online at http://dx.doi.org/10.1016/j.celrep.2015.01.053.

**AUTHOR CONTRIBUTIONS**

H.A. wrote the paper and conceived and performed the majority of the bioinformatics, cloning, cellular, and microscopy work with the support of M.G. and N.G.; P.V.D. conceived and performed COFRADIC analyses and protocol optimization, data interpretation, and bioinformatics analyses with contributions from K.G.; M.G. performed the carbonate wash assay and several knockdowns and validations; K.K.S. prepared cell fractions for COFRADIC and performed initial co-localization experiments with the help of C.H.; M.M. and T.V.K. acquired data on Golgi fragmentation upon NAA60 knockdown; S.I.S. performed in vitro acetylation assays; M.N. developed the PROMPT assay with the contributions of M.Z, S.L., and C.F.; K.H. performed NAA60 knockdown and antibody tests; and T.A. conceived, initiated, and supervised the project and wrote the paper together with H.A.
with the Golgi complex. We aimed to characterize the topology of organellar NAT and establish its membranous association because no organelle-associated NAT has been identified.

Studies of substrate Nt-acetylation have primarily focused on only Naa40, directly (Hole et al., 2011; Polevoda et al., 2009). So far, the majority of soluble yeast (>50%) and human (>80%) proteins have been shown to be post-translationally Nt-acetylated. While some cytosolic and soluble proteins, and it has been shown that a typical organellar localization pattern, as opposed to Naa10, Naa11, Naa20, Naa30, Naa40, Naa50, Naas. HeLa cells expressing C-terminally V5-tagged Naa10, Naa11, Naa20, Naa30, Naa40, Naa50, and Naa60 were subjected to immunocytochemistry. Only Naa60 showed localization to intracellular membranous compartments other than the nucleus.

(B) Naa60-V5 expressing HeLa cells were co-immunostained with anti-V5 and anti-GM130. Low-Naa60-V5-expressing cells are shown.

(C) HeLa cells were treated with brefeldin A (BFA) and co-immunostained with anti-Naa60 and antibodies toward the cis/medial-Golgi marker Giantin. As for Giantin, the perinuclear Golgi signal of Naa60 was lost after BFA treatment. Scale bars, 10 μm. See also Figures S1 and S3A.
Figure S1. Additional co-localization studies related to Figure 1.
Figure S1. Additional co-localization studies related to Figure 1. Weak to absent co-localizations were observed for tagged and endogenous Naa60 with various markers for the secretory and endocytic pathway. The first column shows either endogenous or overexpressed tagged Naa60 as indicated; the second column shows the subcellular markers; and the third column shows an overlay and the rightmost column a zoomed-in area marked in the preceding. Note that there is a difference the localization pattern of endogenous Naa60 (Naa60), which was more confined to the Golgi, and overexpressed tagged Naa60 (Naa60-tGFP), which was more widely distributed to other intracellular organelles. The following organelle markers were used: PMP70: peroxisomes; EEA1: early endosomes; LAMP1: lysosomes; HSA (human serum albumin): secretory vesicles; SCG2 (secretogranin II): secretory vesicles; PDI: ER. Scale bar: 10 μm.
overexpressed Naa60-tGFP was observed to co-distribute well with the ER marker PDI (Figure S1).

Naa60 Localization Depends on a C-Terminal Membrane-Integrating Region

To investigate whether Naa60 contains targeting signals responsible for its distinct organellar localization, we identified specific regions unique for Naa60 among the catalytic Naas. The catalytic subunits Naa30 and Naa50 that have overlapping substrate specificities with Naa60 are also phylogenetically most closely related. Recently, the crystal structure of Naa50 was resolved, thereby providing a compatible reference for Naa60 (Liszczak et al., 2011). By using published alignments (Van Damme et al., 2011b) and comparing those to the Naa50 structure (Liszczak et al., 2011), we found three regions of potential interest (indicated in blue in Figure 2A): (1) the first 13 amino acids (aa) in the N terminus, potentially serving as an N-terminal targeting sequence; (2) aa 78–87, an extended sequence located between the region corresponding to β strands 3 and 4 in the Naa50 structure (Liszczak et al., 2011), predicted as an extended loop; and (3) aa 180–242 at the C terminus, representing an extension only present in Naa60. The latter also contains a predicted putative di-leucine endo/lysosomal-targeting signal QAHSLL (aa 216–221) (by Eukaryotic Linear Motif [ELM]), highlighted in red in Figure 2A. Furthermore, the C-terminal region contained two putative transmembrane domains (TMDs) in regions 193–213 and 217–236 predicted with a low probability (by TMpred, TopPred, PRODIV PRO, and MEMSAT3). We also found two putative S-palmitoylation sites on C207 and C222 (by CCS-Palm 3.0). Of note, other weak transmembrane predictions were found for regions around 52–69 (by TMpred, TMHMM, PRODIVPRO, SCAMPI-msa, OCTOPUS, TOPCONS, and MEMSAT-SVM) and 84–104 (by TMpred and TopPred), but these were considered unlikely, since they comprise part of the predicted GNAT domain and align to β strands 3 and 4 of Naa50 (Liszczak et al., 2011) and Naa10 (Liszczak et al., 2013). Examining Naa50 with several TM databases revealed that these areas could be misread as potential transmembrane regions, likely owing to the fact that GNATs in general have several hydrophobic interactions in these structural domains (Dyda et al., 2000).

Based on these predictions, we made truncation and deletion mutants (Figure 2B) and investigated their subcellular localization (Figure 2C). The Naa60 C Terminus Is Required and Sufficient for Membrane Localization and Integration

(A) The Naa60 protein sequence with predicted motifs and domains indicated. Dark purple, transmembrane domains (predicted with low probability); blue underlined, regions unique for Naa60 among the catalytic Naas (aa 1–13, 78–87, and 180–242); red underlined, putative endo/lysosomal targeting signal, QAHSLL (aa 216–221); C207 and C222 were predicted as putative S-palmitoylation sites by CCS-Palm 3.0. The primary sequence constituting the GNAT-domain together with the core of the Ac-CoA-binding motif Q/RxxGxG/A is indicated above.

(B) Naa60 constructs used for localization studies. Color-coding as in (A).

(C) HeLa cells were transfected with the indicated constructs and fixed. The membrane localization observed for the full-length Naa60 (Naa601–242) was lost by deleting the last 58 amino acids (Naa601–184). eGFP-Naa60182–242 showed a localization pattern resembling that of full-length C-terminally tagged Naa60 whereas a shorter construct, eGFP-Naa60217–242 localized to the cytosol and nucleus. Naa601–242 and Naa601–184 were expressed from plasmid without tag and detected with anti Naa603–77. Scale bar, 10 μm. See also Figure S2.

(D) HeLa cells expressing untagged Naa60 were subjected to subcellular fractionation yielding an organellar pellet (P1), which was dissolved in either sucrose buffer (pH 7.4) or sodium carbonate buffer (pH 11.5) prior to a second centrifugation yielding two sets of P2s and S2s. Naa60 shared its western blot profile with the non-extractable integral membrane proteins Calnexin and RCAS1, as opposed to the peripheral membrane protein GM130, which was extractable by the alkaline buffer.

See also Figure S2.
was observed for the N-truncated eGFP-Naa60 variant, eGFP-
that the amino end of Naa60 also faces the cytosol. The same
permeabilized cells (anti-GFP visualized by red secondary antibody in the digitonin-
determined by PROMPT. eGFP-Naa60 was also detected by
182–242
Figure 4, panel 3), thus demonstrating

Figure 3. PROtease Assay for Membrane Protein Topology, or PROMPT
(A) Principle and constructs of PROMPT. The protein of interest (POI) is expressed with a
C-terminal double-fluorescent reporter tag composed of eGFP (green) and mCherry (red).
PROMPT determines the membrane topology of the POI by organelle-specific proteolytic cleavage of the red fluorescent portion from the PROMPT construct. The endogenous Golgi-localized protease, Furin, will find its recognition site (rs) when the POI C terminus faces the Golgi (left), whereas the ectopic-expressed VP24 will cleave PROMPT constructs when the C terminus of the POI is cytosolic (right). Controls include experiments performed in the absence of VP24 or with a POI construct harboring a mutated Furin recognition site.
(B–D) Validation of PROMPT assay. HeLa S3 (B) or
293 cells (C and D) expressing the indicated constructs were fixed and subjected to fluorescence microscopy (B) or harvested for western blotting (C and D). Furin-mediated cleavage occurred on the CD38-construct only in the presence of an intact Furin recognition site (B and C). The CD4 construct was cleaved not by Furin but by the co-expressed cytosolic VP24 (B and D).
(E and F) Determination of Naa60’s C-terminal topology by the PROMPT assay. NAA60 was subcloned into the PROMPT constructs shown in (A) and expressed in 293 cells, which were fixed and subjected to fluorescence microscopy (E) or western blotting (F). The Naa60 construct was subject to cleavage not by Furin but by the co-expressed cytosolic VP24. Scale bars, 20 μm (B) and 10 μm (E). rs, recognition site; Mut., mutated; -PROMPT, POI-eGFP-[VP24 rs]-[Furin rs]-mCherry; -PROMPT (F). POI-eGFP-
[VP24 rs]-[Mut. Furin rs]-mCherry; filled arrow, intact fusion protein; framed arrow, cleaved fusion protein.
that the amino end of Naa60 also faces the cytosol. The same

Figure 3. PROtease Assay for Membrane Protein Topology, or PROMPT

(A) Principle and constructs of PROMPT. The protein of interest (POI) is expressed with a C-terminal double-fluorescent reporter tag composed of eGFP (green) and mCherry (red). PROMPT determines the membrane topology of the POI by organelle-specific proteolytic cleavage of the red fluorescent portion from the PROMPT construct. The endogenous Golgi-localized protease, Furin, will find its recognition site (rs) when the POI C terminus faces the Golgi (left), whereas the ectopic-expressed VP24 will cleave PROMPT constructs when the C terminus of the POI is cytosolic (right). Controls include experiments performed in the absence of VP24 or with a POI construct harboring a mutated Furin recognition site.

(B–D) Validation of PROMPT assay. HeLa S3 (B) or 293 cells (C and D) expressing the indicated constructs were fixed and subjected to fluorescence microscopy (B) or harvested for western blotting (C and D). Furin-mediated cleavage occurred on the CD38-construct only in the presence of an intact Furin recognition site (B and C). The CD4 construct was cleaved not by Furin but by the co-expressed cytosolic VP24 (B and D).

(E and F) Determination of Naa60’s C-terminal topology by the PROMPT assay. NAA60 was subcloned into the PROMPT constructs shown in (A) and expressed in 293 cells, which were fixed and subjected to fluorescence microscopy (E) or western blotting (F). The Naa60 construct was subject to cleavage not by Furin but by the co-expressed cytosolic VP24.

Scale bars, 20 μm (B) and 10 μm (E). rs, recognition site; Mut., mutated; -PROMPT, POI-eGFP-[VP24 rs]-[Furin rs]-mCherry; -PROMPT (F-), POI-eGFP-[VP24 rs]-[Mut. Furin rs]-mCherry; filled arrow, intact fusion protein; framed arrow, cleaved fusion protein.
was observed for the N-truncated eGFP-Naa60 variant, eGFP-
that the amino end of Naa60 also faces the cytosol. The same
permeabilized cells (anti-GFP visualized by red secondary antibody in the digitonin-
determined by PROMPT. eGFP-Naa60 was also detected by
Figure 4, panel 3), thus demonstrating
the cytosolic side of the intracellular membranes. In summary,
Figure 3. PROtease Assay for Membrane Protein Topology, or PROMPT
(A) Principle and constructs of PROMPT. The protein of interest (POI) is expressed with a C-terminal double-fluorescent reporter tag composed of eGFP (green) and mCherry (red). PROMPT determines the membrane topology of the POI by organelle-specific proteolytic cleavage of the red fluorescent portion from the PROMPT construct. The endogenous Golgi-localized protease, Furin, will find its recognition site (rs) when the POI C terminus faces the Golgi (left), whereas the ectopic-expressed VP24 will cleave PROMPT constructs when the C terminus of the POI is cytosolic (right). Controls include experiments performed in the absence of VP24 or with a POI construct harboring a mutated Furin recognition site.
(B–D) Validation of PROMPT assay. HeLa S3 (B) or 293 cells (C and D) expressing the indicated constructs were fixed and subjected to fluorescence microscopy (B) or harvested for western blotting (C and D). Furin-mediated cleavage occurred on the CD38-construct only in the presence of an intact Furin recognition site (B and C). The CD4 construct was cleaved not by Furin but by the co-expressed cytosolic VP24 (B and D).
(E and F) Determination of Naa60’s C-terminal topology by the PROMPT assay. NAA60 was subcloned into the PROMPT constructs shown in (A) and expressed in 293 cells, which were fixed and subjected to fluorescence microscopy (E) or western blotting (F). The Naa60 construct was subject to cleavage not by Furin but by the co-expressed cytosolic VP24.
Scale bars, 20 μm (B) and 10 μm (E). rs, recognition site; Mut., mutated; -PROMPT, POI-eGFP-[VP24 rs]-[Furin rs]-mCherry; -PROMPT (F-), POI-eGFP-[VP24 rs]-[Mut. Furin rs]-mCherry; filled arrow, intact fusion protein; framed arrow, cleaved fusion protein.
was observed for the N-truncated eGFP-Naa60 variant, eGFP-
that the amino end of Naa60 also faces the cytosol. The same
anti-GFP visualized by red secondary antibody in the digitonin-
determined by PROMPT. eGFP-Naa60 was also detected by
Cell Reports
182–242
, indicative of amino acid 182's cytosolic residence.

Figure 4, panel 3), thus demonstrating
ª
2015 The Authors
Naa60
was observed for the N-truncated eGFP-Naa60 variant, eGFP-
determining the cytosolic residency of their respective regions. All these antibodies pro-
mine the topology of these regions. In summary,

Figure 3. PROtease Assay for Membrane Protein Topology, or PROMPT
(A) Principle and constructs of PROMPT. The protein of interest (POI) is expressed with a C-terminal double-fluorescent reporter tag composed of eGFP (green) and mCherry (red). PROMPT determines the membrane topology of the POI by organelle-specific proteolytic cleavage of the red fluorescent portion from the PROMPT construct. The endogenous Golgi-localized protease, Furin, will find its recognition site (rs) when the POI C terminus faces the Golgi (left), whereas the ectopic-expressed VP24 will cleave PROMPT constructs when the C terminus of the POI is cytosolic (right). Controls include experiments performed in the absence of VP24 or with a POI construct harboring a mutated Furin recognition site.

(B–D) Validation of PROMPT assay. HeLa S3 (B) or 293 cells (C and D) expressing the indicated constructs were fixed and subjected to fluorescence microscopy (B) or harvested for western blotting (C and D). Furin-mediated cleavage occurred on the CD38-construct only in the presence of an intact Furin recognition site (B and C). The CD4 construct was cleaved not by Furin but by the co-expressed cytosolic VP24 (B and D).

(E and F) Determination of Naa60’s C-terminal topology by the PROMPT assay. NAA60 was subcloned into the PROMPT constructs shown in (A) and expressed in 293 cells, which were fixed and subjected to fluorescence microscopy (E) or western blotting (F). The Naa60 construct was subject to cleavage not by Furin but by the co-expressed cytosolic VP24.

Scale bars, 20 μm (B) and 10 μm (E). rs, recognition site; Mut., mutated; -PROMPT, POI-eGFP-[VP24 rs]-[Mut. Furin rs]-mCherry; filled arrow, intact fusion protein; framed arrow, cleaved fusion protein.
Figure S2. Minor or no impact on Naa60 membrane localization for the additional regions shown in Figure 2A. HeLa cells expressing the indicated constructs.

(A) N-terminal truncation (Naa60<sub>14-242</sub>-tGFP) and N-terminal tagging (eGFP-Naa60) interfered somewhat with the localization pattern of Naa60. Note also that, expressing N-terminally tagged Naa60 resulted in increased appearance of enlarged misshaped vacuoles.

(B) Deletion of aa 78-87 putative loop (Naa60<sub>78-87Δ</sub>-tGFP) did not perturb Naa60 membrane localization. Mutation (Naa60<sub>L220/221A</sub>-tGFP) or deletion (Naa60<sub>216-221Δ</sub>-tGFP) of the QAHSLL putative endo/lysosomal targeting signal did not have any detectable effect on Naa60 membrane localization.

(C) Naa60 Cys-Ser mutations did not disrupt Naa60 membrane localization. Several variants of single and multiple mutations were performed. The most extensive are shown.

(D) 2-bromo palmitate (2-BP)-treatment did not detach Naa60 from organelles but somewhat affected Naa60 subcellular distribution, as vesicles appeared typically larger as well as less abundant in the cell periphery. Scale bar: 10 μm.
Figure S2. Minor or no impact on Naa60 membrane localization for the additional regions shown in Figure 2A.
The subcellular localization of its substrates. In order to identify Transmembrane Proteins, we found all the tested parts of Naa60 to reside at the cytosolic side of intracellular membranes. Given the unique localization of Naa60, we wondered about its potential organellar substrates.  

Interestingly, given the organellar localization of Naa60, interestingly, given the enrichment of N-terminal sequences in vitro (MVSM and MKQY peptides; determined Naa60 substrate specificity (Table S1), and recombinant Naa60-acetylated corresponding peptides sequences in vitro. The potential organellar substrates of Naa60, all the substrates were identified in the organellar fraction and insoluble extracts of control small interfering RNA (siRNA)-treated cells resulting in the identification of 21 out of the 23 substrates are established and/or predicted transmembrane proteins. Furthermore, among these transmembrane substrate proteins, there was a clear overrepresentation of N-terminal sequences.

Table 1

Table 1

<table>
<thead>
<tr>
<th>Number</th>
<th>Image Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>1</td>
<td>PDI: luminal Calnexin C-terminus: cytosolic</td>
</tr>
<tr>
<td>2</td>
<td>Naa60 C-terminus: cytosolic</td>
</tr>
<tr>
<td>3</td>
<td>Naa60 N-terminus: cytosolic</td>
</tr>
<tr>
<td>4</td>
<td>Naa60 (aa 182): cytosolic</td>
</tr>
<tr>
<td>5</td>
<td>Naa60 (aa 3-77): cytosolic</td>
</tr>
<tr>
<td>6</td>
<td>Naa60 (aa 69-82): cytosolic</td>
</tr>
<tr>
<td>7</td>
<td>Naa60 (aa 192-241): cytosolic</td>
</tr>
</tbody>
</table>

Figure 4. Naa60 Faces the Cytosol

HeLa cells were subjected to selective membrane permeabilization immunofluorescence. All probed regions of Naa60 were mapped to the cytosolic side: panel 2, C-terminally tagged Naa60-V5 detected with anti-V5; panel 3, N-terminally tagged eGFP-Naa60 detected with anti-GFP; panel 4, Naa60 amino acid 182 detected with antibody toward N-terminal tag on truncated NAA60 (eGFP-Naa60); panel 5, Naa60 aa 3–77 detected with antibody toward Naa60 peptide sequence 3–77; panel 6, Naa60 aa 69–82 detected with antibody toward Naa60 peptide sequence 69–82; and panel 7, Naa60 aa 192–241 detected with antibody toward Naa60 peptide sequence 192–241. Lumenal PDI and cytosolic Calnexin controls (panel 1) were performed in all experiments. In addition, the PDI control was applied in all cells where this combination of antibodies and/or fluorophores was compatible. Scale bar, 10 μm.
we found all the tested parts of Naa60 to reside at the cytosolic side of intracellular membranes.

The Organellar Nt-Acetylome: Naa60 Nt-Acetylates Transmembrane Proteins

Given the unique localization of Naa60, we wondered about the subcellular localization of its substrates. In order to identify potential organellar substrates of Naa60, we performed crude fractionation of stable isotope labeling by amino acids in cell culture (SILAC)-labeled NAA60 knockdown and control A-431 cells (Figures S3A and S3B) and analyzed both cytosolic and organellar fractions by differential N-terminal combined fractional diagonal chromatography (COFRADIC).

Differential proteome analyses of soluble and insoluble extracts of control small interfering RNA (siCTRL)- and siNAA60-treated cells resulted in the identification of 1,699 unique N termini, i.e., N-termini originating from 1,537 unique proteins, including those of 208 (13%) transmembrane proteins (Table S1) and 23 potential Naa60 substrates (Table 1; Figure S3C).

Interestingly, given the organellar localization of Naa60, all the substrates were identified in the organellar fraction and 21 out of the 23 substrates are established and/or predicted transmembrane proteins. Furthermore, among these transmembrane substrate proteins, there was a clear overrepresentation of N-in topology, which corresponds with the topology of Naa60 established above (Figures 3 and 4). Of note however, identified Naa60 substrates covered a variety of membrane compartments (Table 1; ER, plasma membrane, Golgi apparatus, mitochondria, and vesicular membranes), even though Naa60 mainly resides at the Golgi.

Almost all identified Naa60 substrates matched the previously determined Naa60 substrate specificity (Van Damme et al., 2011b) and recombinant Naa60-acetylated corresponding peptide sequences in vitro (MVSM and MKQY peptides; Figure S3D).
we found all the tested parts of Naa60 to reside at the cytosolic side of intracellular membranes.

The Organellar Nt-Acetylome: Naa60 Nt-Acetylates Transmembrane Proteins

Given the unique localization of Naa60, we wondered about the subcellular localization of its substrates. In order to identify potential organellar substrates of Naa60, we performed crude fractionation of stable isotope labeling by amino acids in cell culture (SILAC)-labeled NAA60 knockdown and control A-431 cells (Figures S3A and S3B) and analyzed both cytosolic and organellar fractions by differential N-terminal combined fractional diagonal chromatography (COFRADIC).

Differential proteome analyses of soluble and insoluble extracts of control small interfering RNA (siCTRL)- and siNAA60-treated cells resulted in the identification of 1,699 unique N termini, i.e., N-termini originating from 1,537 unique proteins, including those of 208 (13%) transmembrane proteins (Table S1) and 23 potential Naa60 substrates (Table 1; Figure S3C).

Interestingly, given the organellar localization of Naa60, all the substrates were identified in the organellar fraction and 21 out of the 23 substrates are established and/or predicted transmembrane proteins. Furthermore, among these transmembrane substrate proteins, there was a clear overrepresentation of N-in topology, which corresponds with the topology of Naa60 established above (Figures 3 and 4). Of note however, identified Naa60 substrates covered a variety of membrane compartments (Table 1; ER, plasma membrane, Golgi apparatus, mitochondria, and vesicular membranes), even though Naa60 mainly resides at the Golgi.

Almost all identified Naa60 substrates matched the previously determined Naa60 substrate specificity (Van Damme et al., 2011b) and recombinant Naa60-acetylated corresponding peptide sequences in vitro (MVSM and MKQY peptides; Figure S3D),
Table 1. Naa60 Substrates Identified in the COFRADIC Analysis of Fractionated siCTRL and siNAA60 A-431 Cells

<table>
<thead>
<tr>
<th>Nt Sequence Start</th>
<th>Nt-Ac siCTRL (%)</th>
<th>Nt-Ac siNAA60 (%)</th>
<th>Δ Nt-Ac (%)</th>
<th>Protein Description</th>
<th>Annotated TM (Predicted) TMD</th>
<th>N-Term Topology</th>
<th>Subcellular Localizations</th>
</tr>
</thead>
<tbody>
<tr>
<td>MAPKG 1 87 16 71</td>
<td>TRAPy&lt;sup&gt;a&lt;/sup&gt;</td>
<td>translocon-associated protein subunit gamma</td>
<td>√</td>
<td>4</td>
<td>in</td>
<td>ER-M</td>
<td></td>
</tr>
<tr>
<td>MKOYQ 34 79 25 54</td>
<td>TM222</td>
<td>transmembrane protein 222</td>
<td>√</td>
<td>3</td>
<td>in</td>
<td>PM</td>
<td></td>
</tr>
<tr>
<td>MGPGP&lt;sup&gt;b&lt;/sup&gt; 1 71 20 51</td>
<td>MFSD12&lt;sup&gt;a&lt;/sup&gt;</td>
<td>major facilitator superfamily domain-containing protein 12</td>
<td>√</td>
<td>9/9+(1)</td>
<td>out/in</td>
<td>ER-M</td>
<td></td>
</tr>
<tr>
<td>MVSMS 1 85 42 43</td>
<td>LAPTMM4A&lt;sup&gt;a&lt;/sup&gt;</td>
<td>lysosom-&lt;sub&gt;a&lt;/sub&gt;al-associated transmembrane protein 4A</td>
<td>√</td>
<td>4</td>
<td>in</td>
<td>ES</td>
<td></td>
</tr>
<tr>
<td>MVIIE 1 76 38 38</td>
<td>UfSP2&lt;sup&gt;a&lt;/sup&gt;</td>
<td>Ufm1-specific protease 2</td>
<td>1</td>
<td>in</td>
<td>Cyto; ER</td>
<td></td>
<td></td>
</tr>
<tr>
<td>MOGKK 1 66 29 37</td>
<td>OATP3A&lt;sup&gt;a&lt;/sup&gt;</td>
<td>solute carrier organic anion transporter family member 3A1</td>
<td>√</td>
<td>12/12+(1)/12+(1)/12+(2)</td>
<td>in</td>
<td>PM</td>
<td></td>
</tr>
<tr>
<td>MAPKG 1 94 60 34</td>
<td>TM208&lt;sup&gt;a&lt;/sup&gt;</td>
<td>transmembrane protein 208</td>
<td>√</td>
<td>2</td>
<td>in</td>
<td>ER-M</td>
<td></td>
</tr>
<tr>
<td>MLAAK&lt;sup&gt;b&lt;/sup&gt; 26 70 39 31</td>
<td>LAT1</td>
<td>large neutral amino acids transporter small subunit 1</td>
<td>√</td>
<td>12/12+(1)</td>
<td>in</td>
<td>C; APM</td>
<td></td>
</tr>
<tr>
<td>MLPST 1 100 72 28</td>
<td>UNC50</td>
<td>protein unc-50 homolog</td>
<td>√</td>
<td>5</td>
<td>in</td>
<td>NIM; GA-M</td>
<td></td>
</tr>
<tr>
<td>MAPDP 1 95 69 26</td>
<td>FADS1</td>
<td>fatty acid desaturase 1</td>
<td>√</td>
<td>3</td>
<td>in</td>
<td>ER-M</td>
<td></td>
</tr>
<tr>
<td>MKAVQ 148 88 64 24</td>
<td>LRC59</td>
<td>leucine-rich repeat-containing protein 59</td>
<td>√</td>
<td>1</td>
<td>out</td>
<td>Mi M; ER-M</td>
<td></td>
</tr>
<tr>
<td>MVGF&lt;sup&gt;b&lt;/sup&gt; 1 90 68 22</td>
<td>CASC4</td>
<td>protein CASC4</td>
<td>√</td>
<td>1</td>
<td>in</td>
<td>M</td>
<td></td>
</tr>
<tr>
<td>AAGGS&lt;sup&gt;c&lt;/sup&gt; 2 80 62 18</td>
<td>GSCR2</td>
<td>glioma tumor suppressor candidate region gene 2 protein</td>
<td>no</td>
<td>—</td>
<td>NU; NO</td>
<td></td>
<td></td>
</tr>
<tr>
<td>MIEES 1 79 62 18</td>
<td>DTN-B</td>
<td>dystrobrevin beta</td>
<td>(1)</td>
<td>out</td>
<td>C</td>
<td></td>
<td></td>
</tr>
<tr>
<td>AA&lt;sup&gt;n&lt;/sup&gt; 2 75 58 17</td>
<td>TMM43</td>
<td>transmembrane protein 43</td>
<td>√</td>
<td>3/3+(1)</td>
<td>in</td>
<td>ER; NIM</td>
<td></td>
</tr>
<tr>
<td>MGELP 1 65 49 17</td>
<td>SFXN3</td>
<td>sideroflexin-3</td>
<td>√</td>
<td>4/4+(1)</td>
<td>out/in</td>
<td>Mito-M</td>
<td></td>
</tr>
<tr>
<td>MTQGK 1 96 82 14</td>
<td>HIAT1</td>
<td>hippocampus abundant transcript 1 protein</td>
<td>√</td>
<td>11</td>
<td>in</td>
<td>M</td>
<td></td>
</tr>
<tr>
<td>MYAPG 1 97 85 12</td>
<td>TM127</td>
<td>transmembrane protein 127</td>
<td>√</td>
<td>4</td>
<td>in</td>
<td>PM; C</td>
<td></td>
</tr>
<tr>
<td>MMGLG 1 95 83 11</td>
<td>GOLM1</td>
<td>Golgi membrane protein 1</td>
<td>√</td>
<td>1</td>
<td>in</td>
<td>GA; cis-GA-M</td>
<td></td>
</tr>
<tr>
<td>AATL&lt;sup&gt;c&lt;/sup&gt; 2 61 50 11</td>
<td>PTPM1</td>
<td>phosphatidylglycerophosphatase and protein-tyrosine phosphatase 1</td>
<td>no</td>
<td>—</td>
<td>MIM</td>
<td></td>
<td></td>
</tr>
<tr>
<td>MVS&lt;sup&gt;a&lt;/sup&gt; 1 14 3 11</td>
<td>UXS1</td>
<td>UDP-glucuronic acid decarboxylase 1</td>
<td>√</td>
<td>1</td>
<td>in</td>
<td>GA-M</td>
<td></td>
</tr>
<tr>
<td>AA&lt;sup&gt;v&lt;/sup&gt; 2 33 22 10</td>
<td>HACD2</td>
<td>very-long-chain (3R)-3-hydroxyacyl-[acyl-carrier protein] dehydratase 2</td>
<td>√</td>
<td>9/4+(1)</td>
<td>in/out</td>
<td>ER-M</td>
<td></td>
</tr>
<tr>
<td>MAPMG 1 8 0 8</td>
<td>IMP3</td>
<td>inositol monophosphatase 3</td>
<td>√</td>
<td>1/1+(1)/1+(2)</td>
<td>in</td>
<td>M</td>
<td></td>
</tr>
</tbody>
</table>

See also Table S1 for a complete list of all N termini identified. Abbreviations: ΔNt-Ac, difference in degree of Nt-acetylation between siCTRL and siNAA60 samples; M, membrane; ES, endomembrane system; PM, plasma membrane; C, cytoplasm; cytosol; APM, apical membrane; NIM, nucleus inner membrane; GA, Golgi apparatus; Mi, microsome; NU, nucleus; NO, nucleolus; Mito, mitochondrion; MIM, mitochondrion inner membrane.

<sup>a</sup>Substrates used in follow-up studies (Figure S3E).

<sup>b</sup>N termini whose mass spectrometry spectra are shown in Figure S3C.

<sup>c</sup>Possibly indirectly affected by NAA60 knockdown.
**Figure S3. COFRADIC-related validations, representative MS spectra, *in vitro* peptide acetylation, and substrate localization analysis, supporting Table 1.**

(A) Validation of the subcellular fractionation procedure to generate organelle- and cytosol-enriched proteome fractions. A-431 cells were subjected to crude subcellular fractionation by means of differential centrifugation. Endogenous Naa60 co-segregated with the organelle marker LAMP1 (Pellet (3x)), whereas Naa10 and Naa30 were present in the cytosolic fraction (Super (1x)). 3x refers to 3 equivalents of lysate input to improve immunodetection.

(B) Validation of samples prepared for COFRADIC. A-431 cells grown in $^{13}$C$_6$-$^{15}$N$_4$ L-arginine-containing medium were treated with non-targeting control siRNA (siCTRL, -) and cells grown in $^{12}$C$_6$ L-arginine-containing medium were treated with siNAA60 (+). After 72 hours cells were subjected to crude subcellular fractionation as in A and subjected to COFRADIC followed by LC-MS/MS analysis. Sample aliquots were analysed by Western blot.

(C) Representative MS spectra of two database annotated and initiator methionine starting N-termini identified as Naa60 substrates by N-terminal COFRADIC. **Upper panel:** MS spectrum of the MFSD12 (CS028) N-terminus (M$_1$GPGP-) showing a $\Delta$Nt-Ac of 51% between the siCTRL (71%) and siNAA60 (20%) setups. **Lower panel:** MS spectrum of the LAT1 N-terminus (M$_2$LAAK-) showing a $\Delta$Nt-Ac of 31% between the siCTRL (70%) and siNAA60 (39%) setups.

(D) NAT activity of recombinant Naa60 towards synthetic oligopeptides. Purified recombinant His-SUMO-Naa60 was mixed with 500 μM Acetyl CoA and 500 μM of the indicated oligopeptides in reaction buffer and incubated at 37°C. Product formation was measured indirectly by adding DTNB and measuring the absorbance at 412 nm. The NAT presumed to be responsible for the different N-terminal peptide sequences *in vivo* is indicated below. * indicate an N-terminus previously determined as a Naa60 substrate (Van Damme et al., 2011) and # indicate N-termini identified as putative Naa60 substrates in the present study (Table 1), where MVSM and MKQY are verified as substrates while AANY is not. (E) Six of the NatF substrates identified by means of N-terminal COFRADIC (Table 1) were tested for potential Nt-acetylation dependent effects on subcellular localization. The criteria for selecting these candidates were: *i*) at least 30% absolute shift in the degree of Nt-acetylation between the two setups analyzed (8 proteins); *ii*) an N-terminal sequence matching the defined substrate specificity of Naa60/NatF (8 proteins); *iii*) a natural N-terminus (starting with a database-annotated iMet) (6
were treated with siNAA60 (+). After 72 hours cells were subjected to crude subcellular fractionation as in A and subjected to COFRADIC followed by LC-MS/MS analysis. Sample aliquots were analysed by Western blot. (C) Representative MS spectra of two database annotated and initiator methionine starting N-termini identified as Naa60 substrates by N-terminal COFRADIC. Upper panel: MS spectrum of the MFSD12 (CS028) N-terminus (M2GPGP-) showing a ΔNt-Ac of 51% between the siCTRL (71%) and siNAA60 (20%) setups. Lower panel: MS spectrum of the LAT1 N-terminus (M2LAAK-) showing a ΔNt-Ac of 31% between the siCTRL (70%) and siNAA60 (39%) setups.

(D) NAT activity of recombinant Naa60 towards synthetic oligopeptides. Purified recombinant His-SUMO-Naa60 was mixed with 500 μM Acetyl CoA and 500 μM of the indicated oligopeptides in reaction buffer and incubated at 37°C. Product formation was measured indirectly by adding DTNB and measuring the absorbance at 412 nm. The NAT presumed to be responsible for the different N-terminal peptide sequences in vivo is indicated below. * indicate an N-terminus previously determined as a Naa60 substrate (Van Damme et al., 2011) and # indicate N-termini identified as putative Naa60 substrates in the present study (Table 1), where MVSM and MKQY are verified as substrates while AANY is not. (E) Six of the NatF substrates identified by means of N-terminal COFRADIC (Table 1) were tested for potential Nt-acetylation dependent effects on subcellular localization. The criteria for selecting these candidates were: i) at least 30% absolute shift in the degree of Nt-acetylation between the two setups analyzed (8 proteins); ii) an N-terminal sequence matching the defined substrate specificity of Naa60/NatF (8 proteins); iii) a natural N-terminus (starting with a database-annotated iMet) (6 proteins); iv) established or predicted as transmembrane (6 proteins); and v) an N-terminus with a predicted N-in topology (6 proteins). This left TRAPγ (an ER-protein that constitutes part of the TRAP-complex (Hartmann et al., 1993)), MFSD12 (a less well studied protein whose related proteins localize to the ER (Angers et al., 2008)), LAPTM4A (localizes to endosomes and lysosomes (Hogue et al., 2002)), UfSP2 (not experimentally proven as transmembrane, but may localize to the ER (Ha et al., 2011)), OATP3A1 (localizes to the plasma membrane (Kindla et al., 2011)), and TM208 (localizes to the ER (Zhao et al., 2013)). A-431 cells were transfected with WT or proline mutant versions (indicated in red) of C-terminally tGFP-tagged substrates as indicated. Scale bar: 10 μm.
Figure S3

(A) Total (1x) Super (1x) Pellet (3x) Naa80

(B) Total Super Pellet siNAA60

(C) (Ac) 696.34 (2+)

(D) N-Acetylated peptide (pmol product/ min/Naa80)

Table 1

- siCtrl (71% Ac-)
- siNAA60 (20% Ac-)
- (Ac) 701.35
- (Ac) 774.39 (3+)
- (Ac) 776.06
- (Ac) 777.72
- (Ac) 779.40
- (Ac) 781 m/z
Figure S3

Figure S3. COFRADIC-related validations, representative MS spectra, *in vitro* peptide acetylation, and substrate localization analysis, supporting Table 1.
indicative of the direct action of Naa60 toward these N termini of transmembrane proteins. Note also that the only two affected substrates not annotated or predicted to have a membrane spanning part (GSCR2 and PTPM1) did not display the canonical Naa60/NatF substrate specificity (MX-); rather, alanine-alanine (AA) and two further transmembrane NAA60-knockdown-affected proteins (TMM43 and HACD2), also corresponded to AA-starting proteins (Table 1). However, recombinant Naa60 did not significantly Nt-acetylate this type of N terminus in vitro (AANY-peptide; Figure S3D), indicating that these particular N termini are indirectly affected by NAA60 knockdown rather than being true substrates.

Figure 5. The Naa60/NatF Substrate Category Is Enriched for Transmembrane Proteins

(A) All unique N termini identified in the siCTRL setup, for which the degree of Nt-acetylation could be determined, were grouped into transmembrane (TM) or non-transmembrane protein N-termini (no TM) and categorized according their NAT specificity profile. The “none” category consists of (M)P- starting N termini that are typically refractory to Nt-acetylation. The color code and intensity reflects the average percentage of Nt acetylation as determined in the siCTRL setup; green and red coloring indicates a degree of Nt acetylation above and below 50%, respectively. (B) Venn diagrams of all N termini (left) and all Naa60/NatF type N termini (right) for which the Nt-acetylation status could be determined in both the siCTRL and siNAA60 setups, grouped into transmembrane and non-transmembrane proteins. (C) Bar chart plotting the occurrence of N termini (i.e.: all Swiss-Prot N termini, all N termini identified in this study, Naa60 substrate N termini identified in this study, and Naa30 substrate N termini; T.V.K., P.V.D., K.K.S., K.G., T.A., V. Jonckheere, L.M. Myklebust, G. Bjørkøy, and J.E. Varhaug, unpublished data) for non-transmembrane and signal-containing proteins, non-transmembrane proteins without signal sequence, transmembrane and signal-containing proteins, and transmembrane proteins without signal sequence.
Figure 5. The Naa60/NatF Substrate Category Is Enriched for Transmembrane Proteins

(A) All unique N termini identified in the siCTRL setup, for which the degree of Nt-acetylation could be determined, were grouped into transmembrane (TM) or non-transmembrane protein N-termini (no TM) and categorized according their NAT specificity profile. The “none” category consists of (M)P- starting N termini that are typically refractory to Nt-acetylation. The color code and intensity reflects the average percentage of Nt acetylation as determined in the siCTRL setup; green and red coloring indicates a degree of Nt acetylation above and below 50%, respectively.

(B) Venn diagrams of all N termini (left) and all Naa60/NatF type N termini (right) for which the Nt-acetylation status could be determined in both the siCTRL and siNAA60 setups, grouped into transmembrane and non-transmembrane proteins.

(C) Bar chart plotting the occurrence of N termini (i.e.: all Swiss-Prot N termini, all N termini identified in this study, Naa60 substrate N termini identified in this study, and Naa30 substrate N termini; T.V.K., P.V.D., K.K.S., K.G., T.A., V. Jonckheere, L.M. Myklebust, G. Bjørkøy, and J.E. Varhaug, unpublished data) for non-transmembrane and signal-containing proteins, non-transmembrane proteins without signal sequence, transmembrane and signal-containing proteins, and transmembrane proteins without signal sequence.
Figure 6. NAA60 Knockdown Affects Golgi Morphology

(A) Abnormal Golgi morphology was observed in siNAA60-treated, but not siNAA50-treated, HeLa cells immunostained for the cis-Golgi marker GM130 and compared to siCTRL. Images are based on cell counts showing fragmented Golgi in 14% of siCTRL (n = 338), 14% of siNAA50 (n = 263), and 38% of siNAA60 (n = 231). See also Figure S4A for additional statistics.

(B) Reduction in mRNA level after treatment of HeLa cells with smart pool siRNA used in (A). NAA50, NAA60, and ACTIN PCRs were performed on cDNA synthesized from RNA isolates from cells treated with siCTRL, siNAA50 and siNAA60 cells as in (A). This confirmation was performed in all siRNA experiments.

(C) Left: the siNAA60-induced Golgi phenotype could be rescued by Naa60-V5 expression, but not by expressing any of the cytosolic NATs (Naa10-, Naa30-, or Naa50-V5). Cells were treated with siNAA60-4 and, 3–4 hr later, transfected with V5 plasmids encoding the indicated proteins. Naa60-V5 contained silent mutations enabling expression in siNAA60-4-treated cells. The % of cells displaying a fragmented Golgi was counted among V5-positive cells only, except in the siCTRL and the siNAA60-4 samples (bars 1 and 2). Additionally, to exclude plasmid expression efficacies as a confounding variable, an expression control (Naa60-low expr.) was performed where the “siNAA60-4 + Naa60-V5” condition was recounted, only considering the weakest half of the V5-positive cell population. Right: immunofluorescence images from the same experiment as to the left.

(D) siCTRL- and siNAA60-treated cells co-immunostained for GM130 and Mannosidase II (ManII) revealed that these cis- and medial-Golgi markers cohered equally well in control and Golgi phenotypic cells. Three differing degrees of Golgi structural effects observed in the siNAA60 cells are shown.

All scale bars represent 10 μm. See also validating data in Figure S4 and additional data in Figure S5.
Figure 6. NAA60 Knockdown Affects Golgi Morphology

(A) Abnormal Golgi morphology was observed in siNAA60-treated, but not siNAA50-treated, HeLa cells immunostained for the cis-Golgi marker GM130 and compared to siCTRL. Images are based on cell counts showing fragmented Golgi in 14% of sicCTRL (n = 338), 14% of siNAA50 (n = 263), and 38% of siNAA60 (n = 231). See also Figure S4A for additional statistics.

(B) Reduction in mRNA level after treatment of HeLa cells with smart pool siRNA used in (A). NAA50, NAA60, and ACTIN PCRs were performed on cDNA synthesized from RNA isolates from cells treated with siCTRL, siNAA50 and siNAA60 cells as in (A). This confirmation was performed in all siRNA experiments.

(C) Left: the siNAA60-induced Golgi phenotype could be rescued by Naa60-V5 expression, but not by expressing any of the cytosolic NATs (Naa10-, Naa30-, or Naa50-V5). Cells were treated with siNAA60-4 and, 3–4 hr later, transfected with V5 plasmids encoding the indicated proteins. Naa60-V5 contained silent mutations enabling expression in siNAA60-4-treated cells. The % of cells displaying a fragmented Golgi was counted among V5-positive cells only, except in the siCTRL and the siNAA60-4 samples (bars 1 and 2). Additionally, to exclude plasmid expression efficacies as a confounding variable, an expression control (Naa60-low expr.) was performed where the “siNAA60-4 + Naa60-V5” condition was recounted, only considering the weakest half of the V5-positive cell population. Right: immunofluorescence images from the same experiment as to the left.

(D) siCTRL- and siNAA60-treated cells co-immunostained for GM130 and Mannosidase II (ManII) revealed that these cis- and medial-Golgi markers cohered equally well in control and Golgi phenotypic cells. Three differing degrees of Golgi structural effects observed in the siNAA60 cells are shown.

All scale bars represent 10 μm. See also validating data in Figure S4 and additional data in Figure S5.
Figure 6. NAA60 Knockdown Affects Golgi Morphology

(A) Abnormal Golgi morphology was observed in siNAA60-treated, but not siNAA50-treated, HeLa cells immunostained for the cis-Golgi marker GM130 and compared to siCTRL. Images are based on cell counts showing fragmented Golgi in 14% of siCTRL (n = 338), 14% of siNAA50 (n = 263), and 38% of siNAA60 (n = 231). See also Figure S4A for additional statistics.

(B) Reduction in mRNA level after treatment of HeLa cells with smart pool siRNA used in (A). NAA50, NAA60, and ACTIN PCRs were performed on cDNA synthesized from RNA isolates from cells treated with siCTRL, siNAA50 and siNAA60 cells as in (A). This confirmation was performed in all siRNA experiments.

(C) Left: the siNAA60-induced Golgi phenotype could be rescued by Naa60-V5 expression, but not by expressing any of the cytosolic NATs (Naa10-, Naa30- or Naa50-V5). Cells were treated with siNAA60-4 and, 3–4 hr later, transfected with V5 plasmids encoding the indicated proteins. Naa60-V5 contained silent mutations enabling expression in siNAA60-4-treated cells. The % of cells displaying a fragmented Golgi was counted among V5-positive cells only, except in the siCTRL and the siNAA60-4 samples (bars 1 and 2). Additionally, to exclude plasmid expression efficacies as a confounding variable, an expression control (Naa60-low expr.) was performed where the “siNAA60-4 + Naa60-V5” condition was recounted, only considering the weakest half of the V5-positive cell population. Right: immunofluorescence images from the same experiment as to the left.

(D) siCTRL- and siNAA60-treated cells co-immunostained for GM130 and Mannosidase II (ManII) revealed that these cis- and medial-Golgi markers cohered equally well in control and Golgi phenotypic cells. Three differing degrees of Golgi structural effects observed in the siNAA60 cells are shown.

All scale bars represent 10 μm. See also validating data in Figure S4 and additional data in Figure S5.
Figure S4. Experiments supporting the specificity of Golgi phenotype in NAA60 knockdown cells presented in Figure 6.

(A) Left panel: CAL-62 cells immunostained for GM130 after siNAA60 treatment (smart pool). Right panel: quantifications based on cell counting from samples shown in the left panel. Data are from three individual experiments (n=100-150 cells per sample per experiment) for both cell lines. Error bars denote the standard deviations of three independent experiments. siNAA60 significantly differs from siCTRL in both cell lines with (p<0.05, ANOVA, Post Hoc).

(B-C) The NAA60 knockdown Golgi phenotype was verified by two alternative independent siRNAs, siNAA60-3 (30%, n=292) and siNAA60-4 (31%, n=231) (B), as well as an additional knockdown approach where NAA60 shRNA is expressed from an RFP-vector, shNAA60 (shNAA60-89) vs. shCTRL (non-targeting control shRNA-15)

(C). In shRNA-positive cells, the fragmented Golgi phenotype was observed in 16% of shCTRL-15 (n=161) and 52% of shNAA60-89 (n=185) amongst the RFP-positive cells. Scale bars: 10 µm (A, C); 5 µm (B).
Figure S4. Experiments supporting the specificity of Golgi phenotype in NAA60 knockdown cells presented in Figure 6.
Figure S5. NAA60 knockdown did not cause cytoskeletal disassembly or structural perturbation of organelles other than the Golgi fragmentation shown in Figure 6.

(A) The Golgi-localized Giantin was shown to display the same phenotype as GM130, thus verifying Giantin as a marker for knockdown cells similarly as GM130.

(B) The siNAA60-induced structural effect was specific to the Golgi and no alterations were observed for other organelles or for the F-actin or microtubule cytoskeleton. PDI: ER-marker; COX IV: mitochondrial marker; PMP70: peroxisome marker; EEA1: endosomal marker; LAMP1: lysosomal marker; Rhodamine Phalloidin: actin cytoskeleton stain; and β-tubulin: microtubule cytoskeleton. Giantin was used as a Golgi marker when combined with rabbit antibody against EEA1. In all other panels mouse-derived antibodies were used and GM130 was used as Golgi marker. Scale bar: 10μm.
Figure S5. NAA60 knockdown did not cause cytoskeletal disassembly or structural perturbation of organelles other than the Golgi fragmentation shown in Figure 6.
**Table S1. List of 1,699 unique human N-terminal peptides identified, related to Table 1**

List of 1,699 human N-termini identified in the cytoplasmic and organellar-enriched proteome fractions of *siCTRL* and *siNAA60*-treated human A-431 cells. Swiss-Prot accession, identified peptide sequence, start and end positions, and experiment number(s) in which the peptide was identified (1 and 2 indicate cytoplasmic and organelle-enriched fractions, respectively) are shown. NatF substrate, amino acid residue preceding the identified N-terminus (P1; if any), N-terminal modification status/states confirmed by tandem mass spectrometry (MS/MS) (per setup), degree (%) of Nt-acetylation (per setup/difference between setups/in total), number of identified spectra (per setup/in total), and global Nt-modification status in the *siCTRL* setup(s) (N-termini found to be less than 2% Nt-Ac and more than 98% Nt-Ac) were considered as 100% free and 100% Nt-Ac, respectively, when considering their global Nt-Ac status. N.D. (not determined) indicates N-termini where acetylation status could not be calculated. UniProt database primary accession number, protein description, gene symbols, protein length (aa), Gene Ontology terms, subcellular localizations, and, whenever a peptide matched to multiple members of a protein family (redundancy) isoforms are given for all uniquely identified yeast N-termini. Maximum Mascot ion score, delta threshold (= maximum score – minimum threshold), minimum threshold score, confidence level of identification, and C-terminal modification status/states confirmed by MS/MS (in total) are also indicated. N-termini are ranked alphabetically.

(Table uploaded as a separate Excel file)
Table S2. Nt-acetylation status of transmembrane versus non-transmembrane protein N-termini, related to Table 1 and S1 and Figure 5.

<table>
<thead>
<tr>
<th>NAT</th>
<th>Transmembrane</th>
<th></th>
<th>Non-transmembrane</th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Start with Met</td>
<td>Amino 1</td>
<td>Nt-Ac</td>
<td>Start with Met</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Free</td>
<td>Full</td>
<td>Partial</td>
</tr>
<tr>
<td>NatA</td>
<td>0</td>
<td>A</td>
<td>9%</td>
<td>70%</td>
</tr>
<tr>
<td></td>
<td></td>
<td>C</td>
<td>0%</td>
<td>100%</td>
</tr>
<tr>
<td></td>
<td></td>
<td>G</td>
<td>80%</td>
<td>0%</td>
</tr>
<tr>
<td></td>
<td></td>
<td>S</td>
<td>4%</td>
<td>87%</td>
</tr>
<tr>
<td></td>
<td></td>
<td>T</td>
<td>60%</td>
<td>20%</td>
</tr>
<tr>
<td></td>
<td></td>
<td>V</td>
<td>83%</td>
<td>0%</td>
</tr>
<tr>
<td>NatB</td>
<td>1</td>
<td>D</td>
<td>0%</td>
<td>100%</td>
</tr>
<tr>
<td></td>
<td></td>
<td>E</td>
<td>0%</td>
<td>86%</td>
</tr>
<tr>
<td></td>
<td></td>
<td>N</td>
<td>0%</td>
<td>57%</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Q</td>
<td>50%</td>
<td>0%</td>
</tr>
<tr>
<td>NatC</td>
<td>1</td>
<td>I</td>
<td>0%</td>
<td>100%</td>
</tr>
<tr>
<td></td>
<td></td>
<td>L</td>
<td>20%</td>
<td>40%</td>
</tr>
<tr>
<td>Other</td>
<td>0</td>
<td>F</td>
<td>0%</td>
<td>100%</td>
</tr>
<tr>
<td></td>
<td></td>
<td>N</td>
<td>0%</td>
<td>100%</td>
</tr>
<tr>
<td></td>
<td></td>
<td>P</td>
<td>86%</td>
<td>0%</td>
</tr>
<tr>
<td></td>
<td></td>
<td>A</td>
<td>14%</td>
<td>14%</td>
</tr>
<tr>
<td></td>
<td></td>
<td>G</td>
<td>0%</td>
<td>0%</td>
</tr>
<tr>
<td></td>
<td></td>
<td>K</td>
<td>57%</td>
<td>0%</td>
</tr>
<tr>
<td></td>
<td></td>
<td>M</td>
<td>0%</td>
<td>0%</td>
</tr>
<tr>
<td></td>
<td></td>
<td>T</td>
<td>33%</td>
<td>33%</td>
</tr>
<tr>
<td></td>
<td></td>
<td>V</td>
<td>27%</td>
<td>18%</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Y</td>
<td>50%</td>
<td>0%</td>
</tr>
</tbody>
</table>

Grand Total  | Transmembrane  | 18%  | 58%  | 24%  | 82%  | Non-transmembrane | 10%  | 82%  | 8%  | 90%  |

*N-termini are categorized according to their NAT substrate class. Bold numbers indicate categories with notable differences in Nt-acetylation levels between transmembrane and non-transmembrane proteins. (See also Table S1 for a complete list of all N-termini identified).